Shots:

• Bayer Reports the US FDA’s Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D
• The US FDA granted PR to the therapy- allowing the agency to take action on NDA within 6mos. of acceptance compared to 10mos. under standard review
• Finerenone is an investigational- non-steroidal- selective MRA and has showed a reduction in harmful effects of MR overactivation. The therapy has demonstrated positive kidney and CV outcomes in patients with CKD and T2D

 ­ Ref: BusinessWire | Image: Bayer